Intuitive Surgical, Inc. (ISRG)
Intuitive Surgical makes the Da Vinci robotic systems that help surgeons perform complex, minimally invasive operations with greater precision.
Is Intuitive Surgical, Inc. a good stock for a UK beginner?
The honest version: Intuitive Surgical makes the Da Vinci robotic systems that help surgeons perform complex, minimally invasive operations with greater precision.
Over about 2 years to 2026-07-31. This is the share price only; any dividends would add to it. And it's the USD return - as a UK investor your actual £ return also moves with the exchange rate. Past performance is not a guide to the future, and it could just as easily have fallen.
Based on beta - how much the price swings versus the whole market. Bumpier isn't bad; it just means a rougher ride, which matters more the sooner you might need the money.
Prices move on results, news and the mood of the whole market - no single headline explains a day, and a quiet week is usually just noise, not a signal.
Robotic surgery becomes the standard of care for a wider range of medical specialties.
Technological disruption or significant changes in healthcare reimbursement policies.
What does Intuitive Surgical, Inc. do?
The company designs and builds advanced robotic platforms that act as an extension of a surgeon's hands, allowing for smaller incisions and potentially faster patient recovery. They make money not just by selling these expensive machines, but by charging for the specialised instruments and maintenance services required for every single procedure. What moves the needle here is how many hospitals continue to adopt this technology and how often they use the robots for new types of surgeries.
On our factor screen it looks strongest on quality and growth, and weakest on momentum.
- !Pays no dividend - the whole return rides on the share price
- ✓Growing - revenue up about 18% over the year
- ✓Very profitable - turns about 28% of sales into profit
- !High P/E of 40 - big growth is already priced in
- ✓Strong return on shareholder money (ROE 17%)
- Quality screens high (74/100)
- High profit margins suggest a very strong and efficient business model.
- Recurring revenue from tools and services provides a stable income stream.
- Strong market position as a pioneer in robotic-assisted surgery.
- Value screens low (23/100)
- Momentum screens low (9/100)
- Income screens low (16/100)
- Increased competition from other medical technology firms entering the robotic space.
- Potential changes in how healthcare systems pay for robotic procedures.
What do Intuitive Surgical, Inc.'s numbers mean?
How much money does Intuitive Surgical, Inc. make?
Revenue and profit by quarter, and how much of each sale turns into profit.
Does Intuitive Surgical, Inc. pay a dividend?
No - Intuitive Surgical, Inc. doesn't currently pay a dividend, so the whole return would rest on the share price. Plenty of growing companies reinvest their profits instead of paying them out - neither approach is better or worse, they're just different.
More in Healthcare
Eli Lilly
West Pharmaceutical Services, Inc.
Incyte Corporation
The Cigna Group
Zimmer Biomet Holdings, Inc.
Moderna, Inc.
Gilead Sciences, Inc.
Regeneron Pharmaceuticals, Inc.What are the scenarios for Intuitive Surgical, Inc.?
An illustrative range for the year ahead, with the assumption behind each case — not a prediction or a price target.
What are the pros and cons of Intuitive Surgical, Inc.?
How many points the write-up makes each way — a balance check, not a score or verdict.
- High profit margins suggest a very strong and efficient business model.
- Recurring revenue from tools and services provides a stable income stream.
- Strong market position as a pioneer in robotic-assisted surgery.
- The shares are priced at a premium, which can make them sensitive to market sentiment.
- No dividend payments mean investors rely entirely on share price growth.
- High reliance on hospitals having the budget for expensive capital equipment.
- Increased competition from other medical technology firms entering the robotic space.
- Potential changes in how healthcare systems pay for robotic procedures.
- High volatility compared to the broader market due to the high beta.
The write-up's own warning lights — if these start happening, the case above changes.
- A sustained decline in the number of surgeries performed using their robots.
- A major technological breakthrough from a competitor that makes their systems obsolete.
Built from public filings & market prices, checked for an education-only tone, and never a price target. How we make these →
This plain-English summary was auto-generated on 2026-08-01 from public data and checked for an education-only, no-advice tone (the figures above carry their own, usually fresher, 'as of' date). It's information, never a recommendation.